Paradigm Biopharmaceuticals Ltd's (ASX:PAR) Dr Jeannie Joughin speaks to Proactive's Andrew Scott following the news they've enrolled the first patient in the exploratory PARA_OA_008 knee Osteoarthritis (OA) Biomarker study. This participant has been randomised and has begun study procedures, including joint aspiration to collect baseline biomarker synovial fluid Information, at Sportsmed Biologic in Box Hill, Victoria.
Paradigm Biopharmaceuticals updates as first patient dosed in knee osteoarthritis study
